Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan

Phase 3CompletedNCT00150332

Pfizer24 enrolled

Overview

Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * infection due to methicillin-resistant Staphylococcus aureus Exclusion Criteria: * hypersensitivity to linezolid

Pfizer Investigational Site

Kamogawa, Chiba, Japan

Pfizer Investigational Site

Fukuoka, Fukuoka, Japan

Resolution of infection at the time of completion of therapy

Adverse events

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.